- Home
- ADXN vs CERO Comparison
ADXN vs CERO Comparison
Compare ADXN & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- CERO
- Stock Information
- Founded
- ADXN 2002
- CERO 2017
- Country
- ADXN Switzerland
- CERO United States
- Employees
- ADXN N/A
- CERO N/A
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- CERO
- Sector
- ADXN Health Care
- CERO
- Exchange
- ADXN Nasdaq
- CERO Nasdaq
- Market Cap
- ADXN 8.0M
- CERO 9.6M
- IPO Year
- ADXN N/A
- CERO N/A
- Fundamental
- Price
- ADXN $8.73
- CERO $8.25
- Analyst Decision
- ADXN Strong Buy
- CERO Strong Buy
- Analyst Count
- ADXN 1
- CERO 2
- Target Price
- ADXN $30.00
- CERO $45.00
- AVG Volume (30 Days)
- ADXN 1.0K
- CERO 40.2K
- Earning Date
- ADXN 09-01-2025
- CERO 08-29-2025
- Dividend Yield
- ADXN N/A
- CERO N/A
- EPS Growth
- ADXN N/A
- CERO N/A
- EPS
- ADXN 0.10
- CERO N/A
- Revenue
- ADXN $278,508.00
- CERO N/A
- Revenue This Year
- ADXN $86.57
- CERO N/A
- Revenue Next Year
- ADXN N/A
- CERO N/A
- P/E Ratio
- ADXN $0.72
- CERO N/A
- Revenue Growth
- ADXN N/A
- CERO N/A
- 52 Week Low
- ADXN $6.51
- CERO $6.71
- 52 Week High
- ADXN $13.27
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- ADXN 58.21
- CERO 49.24
- Support Level
- ADXN $7.51
- CERO $8.07
- Resistance Level
- ADXN $8.21
- CERO $8.90
- Average True Range (ATR)
- ADXN 0.17
- CERO 0.40
- MACD
- ADXN 0.11
- CERO 0.11
- Stochastic Oscillator
- ADXN 100.00
- CERO 59.38
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.